Big Pharma is in a rut. The industry keeps spending more and yet making fewer scientific breakthroughs.But help is on the way. GlaxoSmithKline recently announced a radical change in R&D spending. The British drug giant will refocus on data analytics, and the link between the immune system and human disease.
Source: forbes.com
Author: Jon Markman
Advertisements
Categories: Articles